Herpes in Biological Technology

Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes

... keratitis, an ocular disease caused by the herpes simplex virus. The FDA has issued an action date ... and clinician. About Herpetic Keratitis herpes simplex virus (HSV) infections are very common, ... outbreaks, with 20,000 primary cases of ocular herpes diagnosed in the U.S. each year. After the ...

NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists

... development programs in onychomycosis, acne, herpes labialis and genital herpes during the American Association of Pharmaceutical ... lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail ...

NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008

... development programs in onychomycosis, herpes labialis, cystic fibrosis and an ... (ACV)- and Foscarnet (FOS)-Resistant herpes Simplex Virus (HSV) 1 and 2, Poster #V-3538 ... Antiviral Nanoemulsion (NB-001) for Recurrent herpes Labialis 11:15 a.m. - 12:15 p.m. Novel ...

Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification

... Prove-it herpes Offers Considerable Cost Savings for Healthcare ... diagnostics. We believe that Prove-it(TM) herpes will gain a considerable slice of that ... tests for hospital laboratories. The Prove-it(TM) herpes test is developed in co-operation with Hospital ...

Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award

... five-percent acyclovir gel-formulation to treat herpes labialis, or cold sores. Pharmacokinetic data ... drug marketed for the treatment of herpes labialis. In addition, the peak tissue levels are ... rights to SoloVir(TM) ETS for the treatment of herpes labialis. Transport is a Massachusetts-based, ...

Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program

... and to support initial research into three new vaccines for E. coli, herpes and syphilis. Announced today, the grant is funded by Washington's$350 ... prevent transmission to humans via meat or waste. -- Develop a herpes vaccine (a joint effort of the Hutchinson Center, IDRI and UW). ...

Dr. Larry Corey Named New Member of the Institutes of Medicine

... studies dealing with the pathogenesis, prevention and treatment of HIV and herpes virus infections. These investigations include the development of experimental vaccines for both genital herpes and HIV. The labs have also pioneered novel tests for diagnosing and ...

Daniel B. Dubin, M.D., Joins NanoBio Corp.'s Board of Directors

... greatly enhance the strategic positioning of our topical treatments for herpes labialis, onychomycosis and other dermatologic infections." A ... platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal ...

/C O R R E C T I O N -- Rosetta Genomics Ltd/

... a viral microRNA found in Human cytomegalovirus (HCMV), a member of the herpes virus family. Conferences and Events Rosetta Genomics presented at ... a viral microRNA found in Human cytomegalovirus (HCMV), a member of the herpes virus family. Conferences and Events Rosetta Genomics presented at ...

Five Questions About Protopic (tacrolimus) Ointment

... be using. Patients also should tell their doctor if they have a skin disease called Netherton's syndrome, or skin infections such as chicken pox or herpes or if they've been told they have a weakened immune system, or are pregnant, breast feeding or planning to become pregnant.(11) Important I ...

High-Tech 'Smart' Face Mask Helps Hong Kong Families Combat Swine Flu

... (viruses) and cell walls (bacteria). BioFriend(TM) kills germs including those that cause Influenza A (including pandemic strains such as H1N1), herpes Simplex, rhinovirus, common colds, measles, pneumonia, SARS, tuberculosis, streptococcus, and MRSA. By targeting only the dangerous elements, ...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

... cells that result initiate a protective cell mediated and antibody immune response. These results were obtained for L.E.A.P.S. vaccines against herpes simplex and HIV. The L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize ...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

... several different L.E.A.P.S. conjugates induced protection and/or improvement in diseases as diverse as rheumatoid arthritis, malaria, TB and herpes simplex viruses. This shows that the L.E.A.P.S. technology can be successfully applied to many different diseases and these results further suggest ...

China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs

... (SFDA) in China for two of its newly developed drugs. Acyclovir gel is used to treat the skin infection due to varicella-zoster virus and the herpes simplex virus. Shuanghuanglian suppositories helps relieve cold and flu symptoms such as fever, cough and sore throat pain. It can also be used to ...

ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs

... has recently announced its acquisition of a series of inhibitors with demonstrated preclinical efficacy against HIV, HCV, HTLV-I, influenza virus, herpes viruses and cancer. These inhibitors were originally discovered and developed by The Proctor & Gamble Company. Lead molecules from the portfolio ...

LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record

... Profectus' broad product pipeline will address Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papilloma Virus (HPV) and herpes Simplex Virus (HSV). The Profectus portfolio has received over $100 million in funding from multiple sources including National Institutes of ...

CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies

... The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as a herpes simplex virus (HSV) glycoprotein, to make a vaccine that induces a defined immune response. The Company hopes to commence clinical trials in humans ...

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

... The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as a herpes simplex virus (HSV) glycoprotein to make a vaccine that induces a defined immune response. Dr. Kenneth S. Rosenthal, Professor of Microbiology, ...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

... immune response. Researchers have found that PS is exposed on the outer membrane of cells infected with HIV, influenza (including avian flu), herpes simplex viruses, hemorrhagic fever viruses, measles and members of the small pox and rabies virus families. Dr. Barton Haynes, director of Duke ...

Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA

... optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. Ocular adverse reactions occurring in 5-15% of subjects in ...

NanoBio Corporation Raises $12 Million in Series B Financing

... This funding follows several recent product announcements by NanoBio, including: -- Phase 2b data indicating that the company's topical herpes labialis product speeds healing as effectively as the leading oral systemic drugs but without safety or toxicity concerns -- Preclinical data ...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

... class, for the treatment of chronic hepatitis C, and is developing other new thiazolides for treating viral diseases including chronic hepatitis B, herpes and influenza. Alinia(R) (nitazoxanide) is approved by the U.S. Food and Drug Administration and marketed by Romark for the treatment of infections ...

Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C

... class, for the treatment of chronic hepatitis C, and is developing other new thiazolides for treating viral diseases including chronic hepatitis B, herpes and influenza. Alinia(R) (nitazoxanide) is approved by the U.S. Food and Drug Administration and marketed by Romark for the treatment of infections ...

Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask

... disrupting their surfaces (viruses) and cell walls (bacteria). BioFriend(TM) kills germs including those that cause Influenza A (including bird flu), herpes Simplex, rhinovirus, common colds, measles, pneumonia, SARS, tuberculosis, streptococcus, and MRSA. By targeting only the dangerous elements, ...

Purdue researcher invents molecule that stops SARS

... the molecular compound that inhibits the virus provides new insights into a group of proteins found in a range of diseases including childhood croup, herpes and cancer, Ghosh said. "The molecular inhibitor we developed is very potent against the SARS virus by binding to and blocking the use of a ...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

... immune response. Researchers have found that PS is exposed on the outer membrane of cells infected with HIV, influenza (including avian flu), herpes simplex viruses, hemorrhagic fever viruses, measles and members of the small pox and rabies virus families. Dr. Barton Haynes, director of Duke ...

Sinovac Reports Third Quarter 2008 Unaudited Financial Results

... 10 million doses. Once the vaccine is successfully launched, Sinovac would provide the Chinese market with a new vaccine against varicella and the herpes zoster virus. During the third quarter, Sinovac advanced the development of its split pandemic influenza vaccine. The Company completed ...

Singapore Medicine - Breakthrough Development of Cell Therapy Treatment for Cancer

... proteins are expressed on the surface of NPC cancer cells, which are useful as therapeutic targets. Epstein-Barr virus or EBV is a member of the herpes virus family. Most people become infected with it at some point in their lives. Of those affected, the majority suffer nothing more than mild ...

NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)

... in both the United States and the European Union." PHN is a chronic painful condition that develops in approximately 20% of patients following a herpes zoster (shingles) outbreak. An estimated one million people in the United States develop shingles annually. Current treatments for PHN include ...

Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer

... target the replication of the human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis C virus (HCV), influenza virus, herpes viruses, and also include broad based inhibitors of cancer. Lead compounds from the series for HIV and cancer have already been tested in Phase 1 ...

BioVex to Present at the UBS Global Life Sciences Conference

... genital herpes, ImmunoVEXHSV2, a novel, live-attenuated vaccine. In pre-clinical studies, ImmunoVEXHSV2 completely prevented all symptoms of genital herpes and triggered a powerful immune response, suggesting that ImmunoVEX HSV2 may be more potent than other HSV-2 vaccines for which data has been ...

David M. Stout Joins NanoBio Corporation's Board of Directors

... lead products are topical lotions and mucosal vaccines to combat a wide array of viruses, bacteria and fungi. They include topical treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and bacterial skin infections (including MRSA), as well as mucosal vaccines for seasonal and ...

Rosetta Genomics Reports First Quarter 2008 Financial Results

... second allowed patent application (10/604,942) is related to microRNA US5-1, a viral microRNA found in Human cytomegalovirus (HCMV), a member of the herpes virus family. Conferences and Events Rosetta Genomics presented at the following conferences and events: - European Society for Medical ...

Rosetta Genomics Announces Allowance of Two Additional microRNA Patents

... second allowed patent application (10/604,942) is related to microRNA US5-1, a viral microRNA found in Human cytomegalovirus (HCMV), a member of the herpes virus family. "Our leading intellectual property portfolio in microRNAs, which now includes two issued and two allowed patents, is a key component ...

Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent

... of selectively removing cancer cells ex vivo from blood stem cells and other organs using various viruses including modified vaccinia viruses, herpes simplex viruses, parapoxviruses and adenoviruses. "This patent broadens coverage in the area of using other modified oncolytic viruses to purge ...

Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15%

... or dose interruption included: application site reactions, phimosis, inguinal lymphadenitis, urethral meatal stenosis, dysuria, genital herpes simplex, vulvitis, hypersensitivity, pruritis, pyodermitis, skin ulcer, erosions in the urethral meatus, and superinfection of warts and ulcers. ...

Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine

... candidiasis in the USA. In addition, two other innovative products are currently in phase III clinical trials: acyclovir Lauriad(R) in oral herpes (based on the same Lauriad(R) muco-adhesive technology as Loramyc(R), which enables targeted release at the disease site) and doxorubicin ...

Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis

... possibly causally related to HUMIRA include lower respiratory infections (including pneumonia, bronchitis), viral infections (including influenza, herpes infections), candidiasis, bacterial infection (including urinary tract infections), upper respiratory infection, dizziness (including vertigo), ...

Company's Partner Completes Trial Production of a New Antiviral Medicine

... of a new antiviral product. This all-natural medicine has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV ...

NanoBio Expands Drug Development Team for Its Anti-Infective Products

... testing through development will be invaluable in testing and developing our current and future products." NanoBio's clinical programs for herpes labialis (cold sores) and onychomycosis (nail fungus) treatment have already yielded promising results, with clinical trials having demonstrated ...